Inhalers
An inhaler platform is a complex mechanical construction and there are several properties that need to be met during the development process.
iconovo.seCrawled Nov 21, 2026
An inhaler platform is a complex mechanical construction and there are several properties that need to be met during the development process.
Iconovo provides end-to-end inhalation development, from molecule to market-ready pharmaceuticals.
ICOcap is a robust, capsule based dry powder inhaler with a unique, grip-friendly, hinge design that ensures ease of use.
ICOpre is a pre-metered dry powder inhaler with a unique design. It features the same easy user operation as Ellipta: Open-Inhale-Close.
ICOres is a flexible multi-dose dry powder inhaler with patient feedback features. It features two separate reservoirs which allows for simultaneous inhalation of two different formulations.
Iconovo’s pipeline tracks progress for each platform and project in partnership with collaborators.
Posted in December 25, 2025 by jerker.stigsson@cloomy.se
Posted in February 17, 2026 by jerker.stigsson@cloomy.se
Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November.
Iconovo has entered a strategic collaboration agreement with Lonza, one of the world’s leading CDMOs in the life sciences industry. The agreement is a long-term partnership between Iconovo and Lonza in spray-dried formulations.
Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report.
Iconovo News
News & events Stay up to date with the latest news and developments For all the latest regulatory press releases – click here Upcoming events BUSINESS MEETINGS AND EVENTS NLS DaysSept 8-9, Stockholm, Sweden IPAC RSSept 16-17, New Jersey, USA CPHIOct 6-8, Milan, Italy World Vaccine CongressOct 19-20, Amsterdam, The Netherlands MVIC SymposiumOct 21-22, Lund, […]
Iconovo’s team consists of specialists collaborating to develop inhalation products.
Our Team Anders MånssonCEO EducationBSc, Business & Economics, Lund University and MBA Business School Lausanne. BackgroundStrong background in the life science industry, having held senior executive positions in large multinationals, such as Ferring Pharmaceuticals and LEO Pharma, as well as CEO and board level roles in several smaller biotech companies. Calo Ahlgren Senior Mechanical engineer EducationMSc. […]
The page describes Anders Månsson’s role as CEO since 2025 and his background in the life science industry.
Pioneering dry powder inhalation products and accelerate access to innovative inhalation medicines where the inhaler and dry powder formulation are optimized together.
Iconovo creates inhaler products with a focus on sustainability and meaningful impact.
Iconovo offers expertise as a speaking partner for inhalation development projects.
Through collaboration, Iconovo advances patented inhaler platforms and drug candidates to early development stages, enabling efficient transition into later phases with partners.
Iconovo develops inhaled medicines, combining patented dry powder inhalers and formulation expertise for end-to-end development.